PRRT - Practical uncertainty...

AppId is over the quota
AppId is over the quota
The Queensland budget measures were described by the Treasurer as "strong medicine" and are a particularly bitter pill to swallow for those in the resources industry. In the interests of returning the Qld budget to surplus as soon as possible, the Qld Government has taken a number of steps to preserve and ensure the growth of the revenue base. In particular changes were made to: the Qld stamp duty rules - including expanding the duty base by making duty payable on direct and indirect transfers of Qld "Exploration Authorities" since 13 January 2012 and other Qld "Resource Authorities" from 21 September 2012, as well as a number of other changes; andthe Qld mining and petroleum royalty arrangements - including royalty payment arrangements and the rates for coal royalties.For transactions involving Qld exploration tenements that occurred between 13 January 2012 and 21 September 2012, action may be required to be taken under the new stamp duty rules by 22 October 2012.

To find out more, read our latest alerts on these topics or register for our briefing to be held in Brisbane office on Friday 12 October 2012 by contacting any of the contacts listed in the below.

Queensland Stamp Duty Changes Changes to mining and petroleum royalty arrangements in Queensland

Memory leak-clinical focus on practical Neurology

These are excerpts from a review in the Medical Journal of Australia (MJA):

Elderly with mild cognitive impairment are at increased risk of progression to dementia but no test is useful in evaluating this risk. Medications are not favorable in mild cognitive impairment.

Physical activity and treatment of high blood pressure decrease the risk of dementia.

In people with Alzheimer's disease, a cholinesterase inhibitor or Memantine (a receptor antagonist, N-methyl-D-aspartate) provides a symptomatic relief. Drugs do not change the progression of the disease.

Psychological and behavioral symptoms are common in Alzheimer's disease.

Atypical antipsychotics reduce agitation and psychosis, but increase the risk of cardiovascular events.

Role in the management of depression antidepressant with mild cognitive impairment is uncertain, but they may increase the risk of falls and delirium.

References:

Memory loss. Leon A Flicker, Andrew H Ford, Christopher D beer and Osvaldo p. Almeida Med J Aust 2012; 196 (2): 114-117.

Image source: hippocampus, from Wikipedia, in the public domain.

View the original article here

Memory leak-clinical focus on practical Neurology

These are excerpts from a review in the Medical Journal of Australia (MJA):

Elderly with mild cognitive impairment are at increased risk of progression to dementia but no test is useful in evaluating this risk. Medications are not favorable in mild cognitive impairment.

Physical activity and treatment of high blood pressure decrease the risk of dementia.

In people with Alzheimer's disease, a cholinesterase inhibitor or Memantine (a receptor antagonist, N-methyl-D-aspartate) provides a symptomatic relief. Drugs do not change the progression of the disease.

Psychological and behavioral symptoms are common in Alzheimer's disease.

Atypical antipsychotics reduce agitation and psychosis, but increase the risk of cardiovascular events.

Role in the management of depression antidepressant with mild cognitive impairment is uncertain, but they may increase the risk of falls and delirium.

References:

Memory loss. Leon A Flicker, Andrew H Ford, Christopher D beer and Osvaldo p. Almeida Med J Aust 2012; 196 (2): 114-117.

Image source: hippocampus, from Wikipedia, in the public domain.

View the original article here

Memory leak-clinical focus on practical Neurology

These are excerpts from a review in the Medical Journal of Australia (MJA):

Elderly with mild cognitive impairment are at increased risk of progression to dementia but no test is useful in evaluating this risk. Medications are not favorable in mild cognitive impairment.

Physical activity and treatment of high blood pressure decrease the risk of dementia.

In people with Alzheimer's disease, a cholinesterase inhibitor or Memantine (a receptor antagonist, N-methyl-D-aspartate) provides a symptomatic relief. Drugs do not change the progression of the disease.

Psychological and behavioral symptoms are common in Alzheimer's disease.

Atypical antipsychotics reduce agitation and psychosis, but increase the risk of cardiovascular events.

Role in the management of depression antidepressant with mild cognitive impairment is uncertain, but they may increase the risk of falls and delirium.

References:

Memory loss. Leon A Flicker, Andrew H Ford, Christopher D beer and Osvaldo p. Almeida Med J Aust 2012; 196 (2): 114-117.

Image source: hippocampus, from Wikipedia, in the public domain.

View the original article here